Note: Reporting of new COVID-19 Case Surveillance data will be discontinued July 1, 2024, to align with the process of removing SARS-CoV-2 infections (COVID-19 cases) from the list of nationally notifiable diseases. Although these data will continue to be publicly available, the dataset will no longer be updated.

Authorizations to collect certain public health data expired at the end of the U.S. public health emergency declaration on May 11, 2023. The following jurisdictions discontinued COVID-19 case notifications to CDC: Iowa (11/8/21), Kansas (5/12/23), Kentucky (1/1/24), Louisiana (10/31/23), New Hampshire (5/23/23), and Oklahoma (5/2/23). Please note that these jurisdictions will not routinely send new case data after the dates indicated. As of 7/13/23, case notifications from Oregon will only include pediatric cases resulting in death.

This case surveillance public use dataset has 12 elements for all COVID-19 cases shared with CDC and includes demographics, any exposure history, disease severity indicators and outcomes, presence of any underlying medical conditions and risk behaviors, and no geographic data.

CDC has three COVID-19 case surveillance datasets:

• COVID-19 Case Surveillance Public Use Data with Geography: Public use, patient-level dataset with clinical data (including symptoms), demographics, and county and state of residence. (19 data elements)
• COVID-19 Case Surveillance Public Use Data: Public use, patient-level dataset with clinical and symptom data and demographics, with no geographic data. (12 data elements)
• COVID-19 Case Surveillance Restricted Access Detailed Data: Restricted access, patient-level dataset with clinical and symptom data, demographics, and state and county of residence. Access requires a registration process and a data use agreement. (33 data elements)

The following apply to all three datasets:

• Data elements can be found on the COVID-19 case report form located at www.cdc.gov/coronavirus/2019-ncov/downloads/pui-form.pdf.
• Data are considered provisional by CDC and are subject to change until the data are reconciled and verified with the state and territorial data providers.
• Some data cells are suppressed to protect individual privacy.
• The datasets will include all cases with the earliest date available in each record (date received by CDC or date related to illness/specimen collection) at least 14 days prior to the creation of the current datasets. This 14-day lag allows case reporting to be stabilized and ensures that time-dependent outcome data are accurately captured.
• Datasets are updated monthly.
• Datasets are created using CDC’s Policy on Public Health Research and Nonresearch Data Management and Access and include protections designed to protect individual privacy.
• For more information about data collection and reporting, please see https://www.cdc.gov/coronavirus/2019-ncov/covid-data/about-us-cases-deaths.html.
• For more information about the COVID-19 case surveillance data, please see https://www.cdc.gov/coronavirus/2019-ncov/covid-data/faq-surveillance.html
  

Overview

The COVID-19 case surveillance database includes individual-level data reported to U.S. states and aut

The New York Times is releasing a series of data files with cumulative counts of coronavirus cases in the United States, at the state and county level, over time. We are compiling this time series data from state and local governments and health departments in an attempt to provide a complete record of the ongoing outbreak.

Since the first reported coronavirus case in Washington State on Jan. 21, 2020, The Times has tracked cases of coronavirus in real time as they were identified after testing. Because of the widespread shortage of testing, however, the data is necessarily limited in the picture it presents of the outbreak.

We have used this data to power our maps and reporting tracking the outbreak, and it is now being made available to the public in response to requests from researchers, scientists and government officials who would like access to the data to better understand the outbreak.

The data begins with the first reported coronavirus case in Washington State on Jan. 21, 2020. We will publish regular updates to the data in this repository.

Note: Reporting of new COVID-19 Case Surveillance data will be discontinued July 1, 2024, to align with the process of removing SARS-CoV-2 infections (COVID-19 cases) from the list of nationally notifiable diseases. Although these data will continue to be publicly available, the dataset will no longer be updated.

Authorizations to collect certain public health data expired at the end of the U.S. public health emergency declaration on May 11, 2023. The following jurisdictions discontinued COVID-19 case notifications to CDC: Iowa (11/8/21), Kansas (5/12/23), Kentucky (1/1/24), Louisiana (10/31/23), New Hampshire (5/23/23), and Oklahoma (5/2/23). Please note that these jurisdictions will not routinely send new case data after the dates indicated. As of 7/13/23, case notifications from Oregon will only include pediatric cases resulting in death.

This case surveillance public use dataset has 19 elements for all COVID-19 cases shared with CDC and includes demographics, geography (county and state of residence), any exposure history, disease severity indicators and outcomes, and presence of any underlying medical conditions and risk behaviors.

Currently, CDC provides the public with three versions of COVID-19 case surveillance line-listed data: this 19 data element dataset with geography, a 12 data element public use dataset, and a 33 data element restricted access dataset.

The following apply to the public use datasets and the restricted access dataset:

• Data elements can be found on the COVID-19 case report form located at www.cdc.gov/coronavirus/2019-ncov/downloads/pui-form.pdf.
• Data are considered provisional by CDC and are subject to change until the data are reconciled and verified with the state and territorial data providers.
• Some data are suppressed to protect individual privacy.
• Datasets will include all cases with the earliest date available in each record (date received by CDC or date related to illness/specimen collection) at least 14 days prior to the creation of the current datasets. This 14-day lag allows case reporting to be stabilized and ensure that time-dependent outcome data are accurately captured.
• Datasets are updated monthly.
• Datasets are created using CDC’s Policy on Public Health Research and Nonresearch Data Management and Access and include protections designed to protect individual privacy.
• For more information about data collection and reporting, please see https://www.cdc.gov/coronavirus/2019-ncov/covid-data/about-us-cases-deaths.html.
• For more information about the COVID-19 case surveillance data, please see https://www.cdc.gov/coronavirus/2019-ncov/covid-data/faq-surveillance.html
  

Overview

The COVID-19 case surveillance database includes individual-level data reported to U.S. states and autonomous reporting entities, including New York City and the District of Columbia (D.C.), as well as U.S. territories and affiliates. On April 5, 2020, COVID-19 was added to the Nationally Notifiable Condition List and classified as “immediately notifiable, urgent (within 24 hours)” by a Council of State and Territorial Epidemiologists (CSTE) Interim Position Statement (<a href="https://cdn.ymaws.com/www.cste.org/resource/resmgr/ps/positionstatement2020/Interim-20-ID-01_COVID

Reporting of new Aggregate Case and Death Count data was discontinued May 11, 2023, with the expiration of the COVID-19 public health emergency declaration. This dataset will receive a final update on June 1, 2023, to reconcile historical data through May 10, 2023, and will remain publicly available.

Aggregate Data Collection Process Since the start of the COVID-19 pandemic, data have been gathered through a robust process with the following steps:

• A CDC data team reviews and validates the information obtained from jurisdictions’ state and local websites via an overnight data review process.
• If more than one official county data source exists, CDC uses a comprehensive data selection process comparing each official county data source, and takes the highest case and death counts respectively, unless otherwise specified by the state.
• CDC compiles these data and posts the finalized information on COVID Data Tracker.
• County level data is aggregated to obtain state and territory specific totals.

This process is collaborative, with CDC and jurisdictions working together to ensure the accuracy of COVID-19 case and death numbers. County counts provide the most up-to-date numbers on cases and deaths by report date. CDC may retrospectively update counts to correct data quality issues.

Methodology Changes Several differences exist between the current, weekly-updated dataset and the archived version:

• Source: The current Weekly-Updated Version is based on county-level aggregate count data, while the Archived Version is based on State-level aggregate count data.
• Confirmed/Probable Cases/Death breakdown:  While the probable cases and deaths are included in the total case and total death counts in both versions (if applicable), they were reported separately from the confirmed cases and deaths by jurisdiction in the Archived Version.  In the current Weekly-Updated Version, the counts by jurisdiction are not reported by confirmed or probable status (See Confirmed and Probable Counts section for more detail).
• Time Series Frequency: The current Weekly-Updated Version contains weekly time series data (i.e., one record per week per jurisdiction), while the Archived Version contains daily time series data (i.e., one record per day per jurisdiction).
• Update Frequency: The current Weekly-Updated Version is updated weekly, while the Archived Version was updated twice daily up to October 20, 2022.

Important note: The counts reflected during a given time period in this dataset may not match the counts reflected for the same time period in the archived dataset noted above. Discrepancies may exist due to differences between county and state COVID-19 case surveillance and reconciliation efforts.

Confirmed and Probable Counts In this dataset, counts by jurisdiction are not displayed by confirmed or probable status. Instead, confirmed and probable cases and deaths are included in the Total Cases and Total Deaths columns, when available. Not all jurisdictions report probable cases and deaths to CDC.* Confirmed and probable case definition criteria are described here:

Council of State and Territorial Epidemiologists (ymaws.com).

Deaths CDC reports death data on other sections of the website: CDC COVID Data Tracker: Home, CDC COVID Data Tracker: Cases, Deaths, and Testing, and NCHS Provisional Death Counts. Information presented on the COVID Data Tracker pages is based on the same source (total case counts) as the present dataset; however, NCHS Death Counts are based on death certificates that use information reported by physicians, medical examiners, or coroners in the cause-of-death section of each certificate. Data from each of these pages are considered provisional (not complete and pending verification) and are therefore subject to change. Counts from previous weeks are continually revised as more records are received and processed.

Number of Jurisdictions Reporting There are currently 60 public health jurisdictions reporting cases of COVID-19. This includes the 50 states, the District of Columbia, New York City, the U.S. territories of American Samoa, Guam, the Commonwealth of the Northern Mariana Islands, Puerto Rico, and the U.S Virgin Islands as well as three independent countries in compacts of free association with the United States, Federated States of Micronesia, Republic of the Marshall Islands, and Republic of Palau. New York State’s reported case and death counts do not include New York City’s counts as they separately report nationally notifiable conditions to CDC.

CDC COVID-19 data are available to the public as summary or aggregate count files, including total counts of cases and deaths, available by state and by county. These and other data on COVID-19 are available from multiple public locations, such as:

https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html

https://www.cdc.gov/covid-data-tracker/index.html

https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html

https://www.cdc.gov/coronavirus/2019-ncov/php/open-america/surveillance-data-analytics.html

Additional COVID-19 public use datasets, include line-level (patient-level) data, are available at: https://data.cdc.gov/browse?tags=covid-19.

Archived Data Notes:

November 3, 2022: Due to a reporting cadence issue, case rates for Missouri counties are calculated based on 11 days’ worth of case count data in the Weekly United States COVID-19 Cases and Deaths by State data released on November 3, 2022, instead of the customary 7 days’ worth of data.

November 10, 2022: Due to a reporting cadence change, case rates for Alabama counties are calculated based on 13 days’ worth of case count data in the Weekly United States COVID-19 Cases and Deaths by State data released on November 10, 2022, instead of the customary 7 days’ worth of data.

November 10, 2022: Per the request of the jurisdiction, cases and deaths among non-residents have been removed from all Hawaii county totals throughout the entire time series. Cumulative case and death counts reported by CDC will no longer match Hawaii’s COVID-19 Dashboard, which still includes non-resident cases and deaths. 

November 17, 2022: Two new columns, weekly historic cases and weekly historic deaths, were added to this dataset on November 17, 2022. These columns reflect case and death counts that were reported that week but were historical in nature and not reflective of the current burden within the jurisdiction. These historical cases and deaths are not included in the new weekly case and new weekly death columns; however, they are reflected in the cumulative totals provided for each jurisdiction. These data are used to account for artificial increases in case and death totals due to batched reporting of historical data.

December 1, 2022: Due to cadence changes over the Thanksgiving holiday, case rates for all Ohio counties are reported as 0 in the data released on December 1, 2022.

January 5, 2023: Due to North Carolina’s holiday reporting cadence, aggregate case and death data will contain 14 days’ worth of data instead of the customary 7 days. As a result, case and death metrics will appear higher than expected in the January 5, 2023, weekly release.

January 12, 2023: Due to data processing delays, Mississippi’s aggregate case and death data will be reported as 0. As a result, case and death metrics will appear lower than expected in the January 12, 2023, weekly release.

January 19, 2023: Due to a reporting cadence issue, Mississippi’s aggregate case and death data will be calculated based on 14 days’ worth of data instead of the customary 7 days in the January 19, 2023, weekly release.

January 26, 2023: Due to a reporting backlog of historic COVID-19 cases, case rates for two Michigan counties (Livingston and Washtenaw) were higher than expected in the January 19, 2023 weekly release.

January 26, 2023: Due to a backlog of historic COVID-19 cases being reported this week, aggregate case and death counts in Charlotte County and Sarasota County, Florida, will appear higher than expected in the January 26, 2023 weekly release.

January 26, 2023: Due to data processing delays, Mississippi’s aggregate case and death data will be reported as 0 in the weekly release posted on January 26, 2023.

February 2, 2023: As of the data collection deadline, CDC observed an abnormally large increase in aggregate COVID-19 cases and deaths reported for Washington State. In response, totals for new cases and new deaths released on February 2, 2023, have been displayed as zero at the state level until the issue is addressed with state officials. CDC is working with state officials to address the issue.

February 2, 2023: Due to a decrease reported in cumulative case counts by Wyoming, case rates will be reported as 0 in the February 2, 2023, weekly release. CDC is working with state officials to verify the data submitted.

February 16, 2023: Due to data processing delays, Utah’s aggregate case and death data will be reported as 0 in the weekly release posted on February 16, 2023. As a result, case and death metrics will appear lower than expected and should be interpreted with caution.

February 16, 2023: Due to a reporting cadence change, Maine’s

Overview

The Marshall Project, the nonprofit investigative newsroom dedicated to the U.S. criminal justice system, has partnered with The Associated Press to compile data on the prevalence of COVID-19 infection in prisons across the country. The Associated Press is sharing this data as the most comprehensive current national source of COVID-19 outbreaks in state and federal prisons.

Lawyers, criminal justice reform advocates and families of the incarcerated have worried about what was happening in prisons across the nation as coronavirus began to take hold in the communities outside. Data collected by The Marshall Project and AP shows that hundreds of thousands of prisoners, workers, correctional officers and staff have caught the illness as prisons became the center of some of the country’s largest outbreaks. And thousands of people — most of them incarcerated — have died.

In December, as COVID-19 cases spiked across the U.S., the news organizations also shared cumulative rates of infection among prison populations, to better gauge the total effects of the pandemic on prison populations. The analysis found that by mid-December, one in five state and federal prisoners in the United States had tested positive for the coronavirus -- a rate more than four times higher than the general population.

This data, which is updated weekly, is an effort to track how those people have been affected and where the crisis has hit the hardest.

Methodology and Caveats

The data tracks the number of COVID-19 tests administered to people incarcerated in all state and federal prisons, as well as the staff in those facilities. It is collected on a weekly basis by Marshall Project and AP reporters who contact each prison agency directly and verify published figures with officials.

Each week, the reporters ask every prison agency for the total number of coronavirus tests administered to its staff members and prisoners, the cumulative number who tested positive among staff and prisoners, and the numbers of deaths for each group.

The time series data is aggregated to the system level; there is one record for each prison agency on each date of collection. Not all departments could provide data for the exact date requested, and the data indicates the date for the figures.

To estimate the rate of infection among prisoners, we collected population data for each prison system before the pandemic, roughly in mid-March, in April, June, July, August, September and October. Beginning the week of July 28, we updated all prisoner population numbers, reflecting the number of incarcerated adults in state or federal prisons. Prior to that, population figures may have included additional populations, such as prisoners housed in other facilities, which were not captured in our COVID-19 data. In states with unified prison and jail systems, we include both detainees awaiting trial and sentenced prisoners.

To estimate the rate of infection among prison employees, we collected staffing numbers for each system. Where current data was not publicly available, we acquired other numbers through our reporting, including calling agencies or from state budget documents. In six states, we were unable to find recent staffing figures: Alaska, Hawaii, Kentucky, Maryland, Montana, Utah.

To calculate the cumulative COVID-19 impact on prisoner and prison worker populations, we aggregated prisoner and staff COVID case and death data up through Dec. 15. Because population snapshots do not account for movement in and out of prisons since March, and because many systems have significantly slowed the number of new people being sent to prison, it’s difficult to estimate the total number of people who have been held in a state system since March. To be conservative, we calculated our rates of infection using the largest prisoner population snapshots we had during this time period.

As with all COVID-19 data, our understanding of the spread and impact of the virus is limited by the availability of testing. Epidemiology and public health experts say that aside from a few states that have recently begun aggressively testing in prisons, it is likely that there are more cases of COVID-19 circulating undetected in facilities. Sixteen prison systems, including the Federal Bureau of Prisons, would not release information about how many prisoners they are testing.

Corrections departments in Indiana, Kansas, Montana, North Dakota and Wisconsin report coronavirus testing and case data for juvenile facilities; West Virginia reports figures for juvenile facilities and jails. For consistency of comparison with other state prison systems, we removed those facilities from our data that had been included prior to July 28. For these states we have also removed staff data. Similarly, Pennsylvania’s coronavirus data includes testing and cases for those who have been released on parole. We removed these tests and cases for prisoners from the data prior to July 28. The staff cases remain.

About the Data

There are four tables in this data:

• covid_prison_cases.csv contains weekly time series data on tests, infections and deaths in prisons. The first dates in the table are on March 26. Any questions that a prison agency could not or would not answer are left blank.

• prison_populations.csv contains snapshots of the population of people incarcerated in each of these prison systems for whom data on COVID testing and cases are available. This varies by state and may not always be the entire number of people incarcerated in each system. In some states, it may include other populations, such as those on parole or held in state-run jails. This data is primarily for use in calculating rates of testing and infection, and we would not recommend using these numbers to compare the change in how many people are being held in each prison system.

• staff_populations.csv contains a one-time, recent snapshot of the headcount of workers for each prison agency, collected as close to April 15 as possible.

• covid_prison_rates.csv contains the rates of cases and deaths for prisoners. There is one row for every state and federal prison system and an additional row with the National totals.

Queries

The Associated Press and The Marshall Project have created several queries to help you use this data:

Get your state's prison COVID data: Provides each week's data from just your state and calculates a cases-per-100000-prisoners rate, a deaths-per-100000-prisoners rate, a cases-per-100000-workers rate and a deaths-per-100000-workers rate here

Rank all systems' most recent data by cases per 100,000 prisoners here

Find what percentage of your state's total cases and deaths -- as reported by Johns Hopkins University -- occurred within the prison system here

Attribution

In stories, attribute this data to: “According to an analysis of state prison cases by The Marshall Project, a nonprofit investigative newsroom dedicated to the U.S. criminal justice system, and The Associated Press.”

Contributors

Many reporters and editors at The Marshall Project and The Associated Press contributed to this data, including: Katie Park, Tom Meagher, Weihua Li, Gabe Isman, Cary Aspinwall, Keri Blakinger, Jake Bleiberg, Andrew R. Calderón, Maurice Chammah, Andrew DeMillo, Eli Hager, Jamiles Lartey, Claudia Lauer, Nicole Lewis, Humera Lodhi, Colleen Long, Joseph Neff, Michelle Pitcher, Alysia Santo, Beth Schwartzapfel, Damini Sharma, Colleen Slevin, Christie Thompson, Abbie VanSickle, Adria Watson, Andrew Welsh-Huggins.

Questions

If you have questions about the data, please email The Marshall Project at info+covidtracker@themarshallproject.org or file a Github issue.

To learn more about AP's data journalism capabilities for publishers, corporations and financial institutions, go here or email kromano@ap.org.

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes

Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.

Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases among people who received additional or booster doses were reported from 31 jurisdictions; 30 jurisdictions also reported data on deaths among people who received one or more additional or booster dose; 28 jurisdictions reported cases among people who received two or more additional or booster doses; and 26 jurisdictions reported deaths among people who received two or more additional or booster doses. This list will be updated as more jurisdictions participate. Incidence rate estimates: Weekly age-specific incidence rates by vaccination status were calculated as the number of cases or deaths divided by the number of people vaccinated with a primary series, overall or with/without a booster dose (cumulative) or unvaccinated (obtained by subtracting the cumulative number of people vaccinated with a primary series and partially vaccinated people from the 2019 U.S. intercensal population estimates) and multiplied by 100,000. Overall incidence rates were age-standardized using the 2000 U.S. Census standard population. To estimate population counts for ages 6 months through 1 year, half of the single-year population counts for ages 0 through 1 year were used. All rates are plotted by positive specimen collection date to reflect when incident infections occurred. For the primary series analysis, age-standardized rates include ages 12 years and older from April 4, 2021 through December 4, 2021, ages 5 years and older from December 5, 2021 through July 30, 2022 and ages 6 months and older from July 31, 2022 onwards. For the booster dose analysis, age-standardized rates include ages 18 years and older from September 19, 2021 through December 25, 2021, ages 12 years and older from December 26, 2021, and ages 5 years and older from June 5, 2022 onwards. Small numbers could contribute to less precision when calculating death rates among some groups. Continuity correction: A continuity correction has been applied to the denominators by capping the percent population coverage at 95%. To do this, we assumed that at least 5% of each age group would always be unvaccinated in each jurisdiction. Adding this correction ensures that there is always a reasonable denominator for the unvaccinated population that would prevent incidence and death rates from growing unrealistically large due to potential overestimates of vaccination coverage. Incidence rate ratios (IRRs): IRRs for the past one month were calculated by dividing the average weekly incidence rates among unvaccinated people by that among people vaccinated with a primary series either overall or with a booster dose. Publications: Scobie HM, Johnson AG, Suthar AB, et al. Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021. MMWR Morb Mortal Wkly Rep 2021;70:1284–1290. Johnson AG, Amin AB, Ali AR, et al. COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021. MMWR Morb Mortal Wkly Rep 2022;71:132–138. Johnson AG, Linde L, Ali AR, et al. COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination — 24 U.S. Jurisdictions, October 3, 2021–December 24, 2022. MMWR Morb Mortal Wkly Rep 2023;72:145–152. Johnson AG, Linde L, Payne AB, et al. Notes from the Field: Comparison of COVID-19 Mortality Rates Among Adults Aged ≥65 Years Who Were Unvaccinated and Those Who Received a Bivalent Booster Dose Within the Preceding 6 Months — 20 U.S. Jurisdictions, September 18, 2022–April 1, 2023. MMWR Morb Mortal Wkly Rep 2023;72:667–669.

NOTE: This dataset has been retired and marked as historical-only. Weekly rates of COVID-19 cases, hospitalizations, and deaths among people living in Chicago by vaccination status and age. Rates for fully vaccinated and unvaccinated begin the week ending April 3, 2021 when COVID-19 vaccines became widely available in Chicago. Rates for boosted begin the week ending October 23, 2021 after booster shots were recommended by the Centers for Disease Control and Prevention (CDC) for adults 65+ years old and adults in certain populations and high risk occupational and institutional settings who received Pfizer or Moderna for their primary series or anyone who received the Johnson & Johnson vaccine. Chicago residency is based on home address, as reported in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE) and Illinois National Electronic Disease Surveillance System (I-NEDSS). Outcomes: • Cases: People with a positive molecular (PCR) or antigen COVID-19 test result from an FDA-authorized COVID-19 test that was reported into I-NEDSS. A person can become re-infected with SARS-CoV-2 over time and so may be counted more than once in this dataset. Cases are counted by week the test specimen was collected. • Hospitalizations: COVID-19 cases who are hospitalized due to a documented COVID-19 related illness or who are admitted for any reason within 14 days of a positive SARS-CoV-2 test. Hospitalizations are counted by week of hospital admission. • Deaths: COVID-19 cases who died from COVID-19-related health complications as determined by vital records or a public health investigation. Deaths are counted by week of death. Vaccination status: • Fully vaccinated: Completion of primary series of a U.S. Food and Drug Administration (FDA)-authorized or approved COVID-19 vaccine at least 14 days prior to a positive test (with no other positive tests in the previous 45 days). • Boosted: Fully vaccinated with an additional or booster dose of any FDA-authorized or approved COVID-19 vaccine received at least 14 days prior to a positive test (with no other positive tests in the previous 45 days). • Unvaccinated: No evidence of having received a dose of an FDA-authorized or approved vaccine prior to a positive test. CLARIFYING NOTE: Those who started but did not complete all recommended doses of an FDA-authorized or approved vaccine prior to a positive test (i.e., partially vaccinated) are excluded from this dataset. Incidence rates for fully vaccinated but not boosted people (Vaccinated columns) are calculated as total fully vaccinated but not boosted with outcome divided by cumulative fully vaccinated but not boosted at the end of each week. Incidence rates for boosted (Boosted columns) are calculated as total boosted with outcome divided by cumulative boosted at the end of each week. Incidence rates for unvaccinated (Unvaccinated columns) are calculated as total unvaccinated with outcome divided by total population minus cumulative boosted, fully, and partially vaccinated at the end of each week. All rates are multiplied by 100,000. Incidence rate ratios (IRRs) are calculated by dividing the weekly incidence rates among unvaccinated people by those among fully vaccinated but not boosted and boosted people. Overall age-adjusted incidence rates and IRRs are standardized using the 2000 U.S. Census standard population. Population totals are from U.S. Census Bureau American Community Survey 1-year estimates for 2019. All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. This dataset reflects data known to CDPH at the time when the dataset is updated each week. Numbers in this dataset may differ from other public sources due to when data are reported and how City of Chicago boundaries are defined. For all datasets related to COVID-19, see https://data.cityofchic

BackgroundPatient symptoms, crucial for disease progression and diagnosis, are often captured in unstructured clinical notes. Large language models (LLMs) offer potential advantages in extracting patient symptoms compared to traditional rule-based information extraction (IE) systems.MethodsThis study compared fine-tuned LLMs (LLaMA2-13B and LLaMA3-8B) against BioMedICUS, a rule-based IE system, for extracting symptoms related to acute and post-acute sequelae of SARS-CoV-2 from clinical notes. The study utilized three corpora: UMN-COVID, UMN-PASC, and N3C-COVID. Prevalence, keyword and fairness analyses were conducted to assess symptom distribution and model equity across demographics.ResultsBioMedICUS outperformed fine-tuned LLMs in most cases. On the UMN PASC dataset, BioMedICUS achieved a macro-averaged F1-score of 0.70 for positive mention detection, compared to 0.66 for LLaMA2-13B and 0.62 for LLaMA3-8B. For the N3C COVID dataset, BioMedICUS scored 0.75, while LLaMA2-13B and LLaMA3-8B scored 0.53 and 0.68, respectively for positive mention detection. However, LLMs performed better in specific instances, such as detecting positive mentions of change in sleep in the UMN PASC dataset, where LLaMA2-13B (0.79) and LLaMA3-8B (0.65) outperformed BioMedICUS (0.60). For fairness analysis, BioMedICUS generally showed stronger performance across patient demographics. Keyword analysis using ANOVA on symptom distributions across all three corpora showed that both corpus (df = 2, p 

Effective June 28, 2023, this dataset will no longer be updated. Similar data are accessible from CDC WONDER (https://wonder.cdc.gov/mcd-icd10-provisional.html).

Deaths involving coronavirus disease 2019 (COVID-19) with a focus on ages 0-18 years in the United States.

Rank, number of deaths, percentage of deaths, and age-specific mortality rates for the leading causes of death, by age group and sex, 2000 to most recent year.

CATCH-UP Focus group and interview participant demographics (N = 27).

The total amount of data created, captured, copied, and consumed globally is forecast to increase rapidly, reaching *** zettabytes in 2024. Over the next five years up to 2028, global data creation is projected to grow to more than *** zettabytes. In 2020, the amount of data created and replicated reached a new high. The growth was higher than previously expected, caused by the increased demand due to the COVID-19 pandemic, as more people worked and learned from home and used home entertainment options more often. Storage capacity also growing Only a small percentage of this newly created data is kept though, as just * percent of the data produced and consumed in 2020 was saved and retained into 2021. In line with the strong growth of the data volume, the installed base of storage capacity is forecast to increase, growing at a compound annual growth rate of **** percent over the forecast period from 2020 to 2025. In 2020, the installed base of storage capacity reached *** zettabytes.

Abstract

The objective of the Nigeria NLPS Phase 2 is to monitor in real-time how the Nigerian households are coping with national and global crises and their effects on the welfare and livelihoods of the households. The households in the Phase 2 are drawn from the sample of households interviewed in GHS-Panel 2018/19 including those interviewed during the Phase 1. This survey has become a flexible tool that contributes to filling critical gaps in information that could be used by the Nigerian government and stakeholders to help design policies to mitigate the negative impacts of the COVID-19 pandemic, the oil prices crises, inflation and global value chain crises, among others. The Nigeria NLPS Phase 2 is designed to accommodate the evolving nature of the crises, including revision of the questionnaire on a bi-monthly basis.

Geographic coverage

National coverage

Analysis unit

• Households
• Individuals

Kind of data

Sample survey data [ssd]

Sampling procedure

BASELINE (ROUND 1): Wave 4 of the GHS-Panel conducted in 2018/19 served as the frame for the Nigeria NLPS surveys. The GHS-Panel sample includes 4,976 households that were interviewed in the post-harvest visit of the fourth wave in January/February 2019. This sample of households is representative nationally as well as across the 6 geopolitical Zones that divide up the country. In every visit of the GHS-Panel, phone numbers are collected from interviewed households for up to 4 household members and 2 reference persons who are in close contact with the household in order to assist in locating and interviewing households who may have moved in subsequent waves of the survey. This comprehensive set of phone numbers as well as the already well-established relationship between NBS and the GHS-Panel households made this an ideal frame from which to conduct the NLPS in Nigeria.

Among the 4,976 households interviewed in the post-harvest visit of the GHS-Panel in 2019, 4,934 (99.2%) provided at least one phone number. Around 90 percent of these households (4,440) provided a phone number for at least one household member while the remaining 10 percent only provided a phone number for a reference person. For the second phase of the NLPS, all 4,440 GHS-Panel households with household member contact details were included in the sample to be contacted. This included the sample of households from the first phase of the NLPS who had household member contact details (2,701 of 3,000). Based on the response rate in the first phase of the NLPS of 65 percent, this was expected to yield an interviewed sample of nearly 2,900 households that is both nationally representative as well as representative of urban and rural areas of the country.

ROUND 2: Interviewers attempted to contact and interview all 2,922 households that were successfully interviewed in the baseline (round 1) of the NLPS Phase 2. The second round of the NLPS Phase 2 also included individual-level data collection on the migration history of household members. For the migration module, information on adult (15 years or older) members of the household was targeted, including respondents that fall into this age range. However, information was not captured for all adult members. In order to limit the burden for respondents and interviewers in cases where the number of adult members is large, a maximum of 6 household members were selected (in addition to the main respondent) to capture information on migration. Therefore, for households with less than 6 adult members, all eligible members were included. However, 93 percent of interviewed households had 6 or less adult members and only 7 percent had more than six. For the 7 percent with more than 6 adult members, 6 members were randomly selected from among the pool of eligible members. The selection was stratified by sex with an equal split of 3 male and 3 females was targeted, depending on the pool of eligible males and females. However, the application of selection as relatively rare.

ROUND 3: Interviewers attempted to contact and interview all 2,811 households that were successfully interviewed in the baseline (round 1) of the NLPS Phase 2, excluding 41 households that refused in Round 2. The third round of the NLPS Phase 2 also included individual-level data collection on employment and job history of household members. For the employment and job history modules, information on adult (15 years or older) members of the household was targeted, including respondents that fall into this age range. However, information was not captured for all adult members. In order to limit the burden for respondents and interviewers in cases where the number of adult members is large, a maximum of 4 household members were selected (in addition to the main respondent) to capture information on employment and job history. Therefore, for households with less than 4 adult members, all eligible members were included.

However, 90 percent of interviewed households had 4 or less adult members and only 10 percent had more than four. For the 10 percent with more than 4 adult members, 4 members were randomly selected from among the pool of eligible members. The selection was stratified by sex with an equal split of 2 male and 2 females was targeted, depending on the pool of eligible males and females. The selection of eligible household members in Round 3 was conditional to the selection conducted in Round 2 for the migration module. In that round, up to 6 household members were selected (15 years or older) to answer the migration module. However, the application of selection as relatively rare.

ROUND 4: Interviewers attempted to contact and interview all 2,852 households that were successfully interviewed in the baseline (round 1) of the NLPS Phase 2, excluding 70 households that refused in previous rounds of the survey.

ROUND 5: Interviewers attempted to contact and interview 2,824 households consisting of households that were successfully interviewed in the baseline (round 1) of the NLPS Phase 2 excluding 98 households that refused in previous rounds of the survey.

ROUND 6: Interviewers attempted to contact and interview 2,799 households consisting of households that were successfully interviewed in the baseline (round 1) of the NLPS Phase 2 excluding 123 households that refused in previous rounds of the survey.

ROUND 7: Interviewers attempted to contact and interview 2,784 households consisting of households that were successfully interviewed in the baseline (round 1) of the NLPS Phase 2 excluding 138 households that refused in previous rounds of the survey.

ROUND 8: Interviewers attempted to contact and interview 2,771 households consisting of households that were successfully interviewed in the baseline (round 1) of the NLPS Phase 2 excluding 151 households that refused in previous rounds of the survey.

ROUND 9: Interviewers attempted to contact and interview 2,753 households consisting of households that were successfully interviewed in the baseline (round 1) of the NLPS Phase 2 excluding 169 households that refused in previous rounds of the survey.

ROUND 10: Interviewers attempted to contact and interview 2,743 households consisting of households that were successfully interviewed in the baseline (round 1) of the NLPS Phase 2 excluding 179 households that refused in previous rounds of the survey.

ROUND 11: Interviewers attempted to contact and interview 2,732 households consisting of households that were successfully interviewed in the baseline (round 1) of the NLPS Phase 2 excluding 190 households that refused in previous rounds of the survey.

ROUND 12: Interviewers attempted to contact and interview 2,724 households consisting of households that were successfully interviewed in the baseline (round 1) of the NLPS Phase 2 excluding 198 households that refused in previous rounds of the survey.

ROUND 13: Interviewers attempted to contact and interview 2,714 households consisting of households that were successfully interviewed in the baseline (round 1) of the NLPS Phase 2 excluding 208 households that refused in previous rounds of the survey.

Mode of data collection

Computer Assisted Telephone Interview [cati]

Research instrument

BASELINE (ROUND 1): One questionnaire, the Household Questionnaire, was administered to all households in the sample. The Household Questionnaire provides information on demographics; access to health services; employment and non-farm enterprise; and COVID-19 vaccine.

ROUND 2: One questionnaire, the Household Questionnaire, was administered to all households in the sample. The Household Questionnaire provides information on demographics; migration; employment; and household migrants.

ROUND 3: One questionnaire, the Household Questionnaire, was administered to all households in the sample. The Household Questionnaire provides information on demographics; access to health services; employment; job history; and COVID-19 vaccine.

ROUND 4: One questionnaire, the Household Questionnaire, was administered to all households in the sample. The Household Questionnaire provides information on demographics; access to health services; petrol; employment; credit; and economic sentiments. While the Household Questionnaire was administered to all the sample households, economic sentiments questions were asked to only half of the sample households (randomly selected).

ROUND 5: One questionnaire, the Household Questionnaire, was administered to all households in the sample. The Household Questionnaire provides information on demographics; access to health services; employment; COVID-19 vaccine; economic sentiments; and farmer screening. While the Household Questionnaire was administered to all the sample households,

Maternal and neonatal demographics and clinical characteristics during pre-COVID (October 19 –March 20) and early COVID periods (April–September 2020) by birth location.